Call for Abstract
4th World Congress on Breast Pathology and Cancer Diagnosis, will be organized around the theme ““Think Pink! Myriad Advancing Women Health & Transfiguring Women’s lives” ”
Breast Pathology 2017 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in Breast Pathology 2017
Submit your abstract to any of the mentioned tracks.
Register now for the conference by choosing an appropriate package suitable to you.
Breast cancer is often thought of as something that only affects women, but men can get it in rare cases. It develops in the small amount of breast tissue men have behind their nipples. It usually occurs in men over 60, but can very occasionally affect younger men. Because so many cases of breast cancer occur in women and it is very rare in men, a lot of the information is directed towards women. But much of the information that men with breast cancer need is the same.
- Track 1-1Risk factors for male breast cancer
- Track 1-2Diagnosis of male breast cancer
- Track 1-3Treatment of male breast cancer
- Track 1-4Trials and research in male breast cancer
One important aspect of the role of Pathology in the evaluation of breast cancer is biomarker testing, specifically the accurate assessment of the estrogen receptor (ER), progesterone receptor (PR), and Her2 status of a patient's breast cancer. Biomarkers can be prognostic, predictive, or both. Prognostic biomarkers are independent measures of prognosis such that the presence or absence of the biomarker is associated with a patient's overall clinical outcome (i.e., risk of recurrence and mortality). Predictive biomarkers, in contrast, predict whether or not a patient will respond to a given therapy.
- Track 2-1Biomarkers in clinical trials of novel therapeutics
- Track 2-2Biomarkers for metastatic breast cancer
- Track 2-3Molecular Imaging of biomarkers in breast cancer
Radiotherapy uses high-energy x-rays to destroy cancer cells. Normal cells can also be damaged by radiotherapy, which may cause side effects. But careful planning and newer ways of giving radiotherapy have reduced the risk of damage to healthy tissue and nearby organs. Cancer cells cannot repair themselves after radiotherapy, but normal cells usually can repair.
- Track 3-1Radiotherapy after breast-conserving surgery
- Track 3-2Radiotherapy after a mastectomy
- Track 3-3Radiotherapy to the lymph nodes
- Track 3-4Side Effects of radiotherapy
- Track 3-5Late effects of radiotherapy
Chemotherapy uses anti-cancer (cytotoxic) drugs to destroy cancer cells. Cytotoxic means toxic to cells. These drugs disrupt the way cancer cells grow and divide, but they also affect normal cells. Some cancer specialist may recommend having chemotherapy after surgery to reduce the risk of breast cancer coming back. This is called adjuvant chemotherapy. Some women have chemotherapy before surgery to shrink a large cancer (neo-adjuvant treatment). If it works well, So one may only need part of the breast removed instead of a mastectomy.
- Track 4-1Being treated with chemotherapy
- Track 4-2Pregnancy and chemotherapy
- Track 4-3Breastfeeding and chemotherapy
The two most common genetic risk factors for breast cancer are the BRCA1 & 2 genes.BRCA1 & BRCA2 Approximately 5% of all breast cancers are caused by a recognised specific genetic predisposition due to germ line mutations of one of two different genes: BRCA1 located on Chromosome 17q, BRCA2 located on Chromosome 13q. BRCA1 mutations also predispose to carcinoma of the ovary and possibly carcinoma of the Fallopian tube .Mutations of this gene are particularly common in Ashkenazy Jews (2%). The risk of developing breast cancer among carriers is around 55% by age 70. BRCA2: The product of BRCA2 is involved in controlling gene function and DNA repair. Gene function involves in transcriptional activation and completion of cell division by cytokinesis. Majority of BRCA2-associated tumours are invasive ductal, no special-type tumours.
- Track 5-1Testing for BRCA1 and BRCA2
- Track 5-2Ataxia Telangiectasia Mutation (ATM)
- Track 5-3Hereditary Breast Cancer
In cancer care, doctors specializing in different areas of cancer treatment—such as surgery, radiation oncology, and medical oncology. Cancer care teams also include a variety of other health care professionals, including physician assistants, oncology nurses, social workers, pharmacists, counsellors, nutritionists, and others. The biology and behaviour of a breast cancer affects the treatment plan. Some tumours are small but grow fast, while others are large and grow slowly. Treatment options and recommendations are very personalized and depend on several factors, including: stage of tumour, tumour subtypes, genomic maker, patient age, and patient menopausal status, mutations in inherited breast cancer genes, such as BRCA1 or BRCA2. For both DCIS and early-stage invasive breast cancer, doctors generally perform surgery to remove the tumour. For larger cancers, or those that are growing more quickly, doctors may recommend systemic treatment with chemotherapy or hormonal therapy before surgery, called neoadjuvant therapy.
- Track 6-1Chemotherapy
- Track 6-2Radiation Therapy
- Track 6-3Reconstructive (plastic) Surgery
- Track 6-4Hormonal therapy for premenopausal women
- Track 6-5Hormonal Therapy for Metastatic Breast Cancer
- Track 6-6Targeted Therapy
- Track 6-7Biological Treatment
- Track 6-8Complementary and Alternative Therapies in Breast Cancer
20% of breast carcinomas are of special type and the majority of these are lobular carcinomas. Tubular and mucinous carcinomas occur next most frequently and thereafter the remaining special types are seen infrequently. In order to make a diagnosis of a special type of carcinoma >90% of the tumour is required to show the particular pattern in question. Special types of carcinoma should be distinguished from mixed carcinomas where the special type areas occupy between 50 and 90% of the tumour area with the remaining area being usually of no special type.
- Track 7-1Invasive Carcinomas of Special Type
- Track 7-2Invasive Tubular Carcinoma
- Track 7-3Invasive Mucinous Carcinoma
- Track 7-4Invasive Medullary-like Carcinoma
The involvement of pathologists in the management of breast disease divided into four main areas: Diagnosis, Assessment of adequacy of treatment and prognosis, effective communication and research.
Biopsy: A breast biopsy is removal of breast tissue for examination by a pathologist.
Needle biopsy: A needle biopsy removes part of the suspicious area for examination. There are two types, aspiration biopsy (using a fine needle), and large core needle biopsy. Either of these may be called a percutaneous needle biopsied/or by an imaging test .a fine needle aspiration biopsy uses a very thin needle to withdraw fluid and cells that can be studied A fine needle aspiration biopsy uses a very thin needle to withdraw fluid and cells that can be studied. X rays can be taken before, during, and after the tissue is drawn into the needle, to confirm that the correct spot is being biopsied. X rays may be taken before, during, and after the tissue is drawn into the needle, to confirm that the correct spot is biopsied. The patient can get back to their normal routine immediately. A normal pathology report indicates no malignancy is present. The tissue sample may be further classified as a benign breast condition, such as tumour of the breast (fibro adenoma). An abnormal pathology report indicates a cancer is present. If a fine needle aspiration biopsy was performed.
- Track 8-1Surgical Biopsy
- Track 8-23D Tomosynthesis in Combination with Mmamography
- Track 8-3Latest diagnostic modalities
- Track 8-4Molecular Breast Imaging (MBI)
- Track 8-5Breast magnetic resonance imaging (MRI)
- Track 8-6 Ultrasound
- Track 8-7Mammography
- Track 8-8Core Biopsy
- Track 8-9Galactography (Ductography)
- Track 8-10Fine Needle Aspiration
In medicine, a case report contains detailed report of the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient. Case report usually describes an unusual or novel occurrence. Case reports are an unexpected association between diseases or symptoms. It may results in finding the shed new light on the possible pathogenesis of a disease or an adverse effect.it may contour Unique or rare features of a disease, unique therapeutic approaches.
- Track 9-1BRCA1, BRCA2 Mutations and Sporadic Cases
- Track 9-2Breast Cancer Biological therapy Side Effects
- Track 9-3Breast Cancer Chemo Side Effects
- Track 9-4Breast Cancer Radiotherapy side effects
- Track 9-5Bilateral Primary Breast Lymphoma
- Track 9-6Carcinoma in situ
- Track 9-7Silicon Breast Implant Capsule
- Track 9-8Liposarcoma of Breast, Angiosarcoma of Breast
- Track 9-9Fibromatosis
- Track 9-10Genetics of Tumour
- Track 9-11Breast Cancer Hormone Therapy Side Effects
Mastectomy is the surgical removal of the entire breast. Some women has the option of mastectomy or lumpectomy (also called breast conserving surgery) plus radiation therapy. Other women can only have mastectomy. Some women have a very high risk of breast cancer due to an inherited gene mutation. These women may have one or both breasts removed to try to prevent breast cancer (called prophylactic mastectomy).A woman at very high risk who has cancer in one breast may have her healthy breast removed to try to prevent breast cancer in the healthy breast (contralateral prophylactic mastectomy)A woman at increased risk who does not have breast cancer, may have both breasts removed to try to prevent breast cancer (bilateral prophylactic mastectomy).
- Track 10-1Total Mastectomy
- Track 10-2Modified Radical Mastectomy
- Track 10-3Breast Reconstruction
- Track 10-4Stem Cell
- Track 10-5Lumpectomy
- Track 10-6Axillary Clearence
There are trillions of cells in the body. These cells have regulated cell cycle that controls their growth, maturity, division and death. During childhood normal cells replicates faster to allow the person to grow. Once adulthood is reached the cells divide to replace worn-out cells and to repair injuries. This cell division and growth is controlled by the cellular blue print or DNA and genes that lie within the cell’s nucleus. Cancer initiate when cells in a part of the body start to grow out of control. All types of cancer, irrespective of their origin, occur due to this uncontrollable growth of cells that leads to formation of tumours and lesions. These cells have longer life spans and instead of dying continue to grow and form new, abnormal cells. Cancer cells can also invade other tissues. This property is called metastasis. Cancer cells grow into tumours that are supplied to blood vessels. This is called angiogenesis. Damage to the DNA and genetic mutations can also lead to breast cancer have been experimentally linked to estrogenic exposure. Some individuals inherit defects in the DNA and genes like the BRCA1, BRCA2 and P53 among others. Those with a family history of ovarian or breast cancer thus are at an increased risk of breast cancer.
- Track 11-1Papillary breast cancer
- Track 11-2Chemotherapy drugs and combination regimens
- Track 11-3Side effects of chemotherapy
- Track 11-4Metastatic breast cancer
- Track 11-5Hormone receptor positive
- Track 11-6HER2 positive
- Track 11-7Triple negative
Non-cancerous breast conditions are most common and most women have them. In fact, most breast changes that are tested turn out to be benign. Benign is another word for non-cancerous. Benign breast conditions are not life-threatening. Benign conditions and breast cancer has many of the same symptoms. So it can be hard to tell the difference from just symptoms alone. Some breast changes may not cause any symptoms and may be found during a mammogram. But sometimes they can cause symptoms that bother. Benign breast tumours may hurt, but they aren’t dangerous and don’t spread from the breast to other organs. Still, some benign breast conditions, such as papilloma’s and atypical hyperplasia, are important to know about because women with them have a higher risk of developing breast cancer. A biopsy is the only way to find out if a lump is benign or cancer. If a benign tumour is large, it may change the breast’s size and shape. If it’s growing into the tissue of the milk ducts, it may cause an abnormal discharge from the nipple. Depending on the type, size, and number of benign tumours, surgery to recommended.
- Track 12-1Fibroadenomas
- Track 12-2Phyllodes Tumours
- Track 12-3Inflammations - abscess
- Track 12-4Gynaecomastia
Psychological stress describes what people feel when they are under mental, physical, or emotional pressure. Although it is normal to experience some psychological stress from time to time, people who experience high levels of psychological stress or who experience it repeatedly over a long period of time may develop health problems (mental and/or physical). Distress has become increasingly recognized as a factor that can reduce the quality of life of cancer patients. There is even some evidence that extreme distress is associated with poorer clinical outcomes. Clinical guidelines are available to help doctors and nurses assess levels of distress and help patients manage it.
- Track 13-1Coping with Breast Cancer
- Track 13-2Living with Breast Cancer Surgery
- Track 13-3Breast Cancer and Preserving Fertility
- Track 13-4Breast Cancer and Menopausal Symptoms
- Track 13-5Emotions and Breast Cancer
- Track 13-6Breast Cancer and Mental Health
- Track 13-7Counseling and Therapy for Cancer
- Track 14-1Medullary Breast Cancer
- Track 14-2Mucoid or Colloid Breast Cancer
- Track 14-3Tubular Breast Cancer
- Track 14-4Metaplastic breast cancer
- Track 14-5Angiosarcoma of the Breast
Timely access to a breast care nurse can greatly assist women going through treatment for breast cancer. Breast care nurses improve the continuity of care for women, and provide important information, support and referral for a wide range of needs experienced by women. Although more detailed research is necessary to answer some of the questions raised by this study, implementing the walking program and forming a support group.
- Track 15-1Standards of care for people with breast cancer
- Track 15-2emotional support with nursing intervention
- Track 15-3Nursing care for women in chemotherapy
- Track 15-4Metastatic breast cancer nursing
- Track 15-5Supporting patients in clinical decision-making
- Track 15-6Complementary therapies in breast cancer nursing.
If tests show that you have breast cancer you will need to have further tests. The tests check the size of the cancer and whether there is any spread to nearby lymph nodes or to other parts of the body. This tells the doctor the stages of cancer. The stage is important because it helps your doctor to decide on the best treatment for you. Most women have blood tests, MRI scan, Lymph node Ultrasound scan and some have a chest X-ray. These may be done as part of standard preparation before surgery.
- Track 16-1MRI Scan
- Track 16-2Lymphnode Ultrasound Scan
- Track 16-3Liver Scan
- Track 16-4Bone Scan
- Track 16-5Hormone Receptor Tests
- Track 16-6Receptor Tests for Her2
Breast cancer is found in about 1 in every 3,000 pregnant women. Breast cancer is the most common type of cancer found during pregnancy, while breastfeeding, or within the first year of delivery. You may hear this called gestational breast cancer or pregnancy-associated breast cancer (PABC). When a pregnant woman develops breast cancer, it’s often diagnosed at a later stage than it would be if the woman were not pregnant. It’s also more likely to have spread to the lymph nodes. This is partly because hormone changes during pregnancy. Another reason it may be hard to find breast cancers early during pregnancy is that screening for breast cancer is often delayed until after the pregnancy is over. Pregnancy and breast feeding can also make breast tissue denser.
- Track 17-1Breast Biopsy During Pregnancy
- Track 17-2Mammography During Pregnancy
- Track 17-3Pregnancy-associated Breast Cancer
- Track 17-4Practical Birth Control Choice
- Track 17-5Pregnancy After Breast Cancer
- Track 17-6Effects of Treatment on Fertility
- Track 17-7Loss of Fertility
- Track 18-1 Approved Drugs to Prevent Breast Cancer
- Track 18-2 Approved Drugs to Treat Breast Cancer
- Track 18-3Drug Combinations Used in Breast Cancer
- Track 18-4Personalized Medicine - Breast Cancer
- Track 19-1Breast Cancer physiotherapy
- Track 19-2Radiation-induced Acute Skin Reactions
Immunohistochemistry has an important role in the pathology of breast disease, as well as in other benign or malignant tumours. Overall, immunotherapy holds several key advantages over conventional chemotherapeutic and targeted treatments directed at the tumour itself. First, immunotherapy generally results in fewer side effects, enabling it to be administered for longer periods of time and/or in combination with other agents without added toxicity. The principal function of immunohistochemistry of breast pathology is: Solving common diagnostic dilemmas e.g., Benign/malignant, Epithelial proliferations, In situ v micro invasion. Tumour typing and confirming diagnoses, such as : Tumour typing ,Subtle foci of invasion, Status of margins, Lymph node metastases, Demonstrating epithelial cells in necrotic material. For confirmation of this diagnosis most frequently used immunostains in breast pathology are: Myoepithelial markers - CK 5/6; P63, Lobular v Ductal - E Cadherin, Receptors - ER; PGR and Her2.
- Track 20-1Immunotherapy
- Track 20-2Adoptive Cell Therapy
- Track 20-3Antibodies
- Track 20-4Cytokines
Preclinical studies is a stage of research that begins before clinical trials (testing in humans) can begin, and during which important feasibility, iterative testing and drug safety data are collected .The main goals of pre-clinical studies are to determine the safe dose for first-in-man study and assess a product's safety profile. Products may include new medical devices, drugs, gene therapy solutions and diagnostic tools. clinical research are the steps in which scientists do experiments with a health intervention in an attempt to find enough evidence for a process which would be useful as a medical treatment. In the case of pharmaceutical study, the phases start with drug design and drug discovery then proceed on to animal testing. If this is successful, they begin the clinical phase of development by testing for safety in a few human subjects and expand to test in many study participants to determine if the treatment is effective.
- Track 21-1Preclinical and Clinical Studies on Targeted Immuno Drug Therapy
- Track 21-2 Preclinical and Clinical Trials with Metformin
- Track 21-3Clinical Trials for Breast Cancer Stage 4
- Track 21-4Clinical Trials for Metastatic Breast Cancer
- Track 21-5Breast Cancer Trial drugs